Digestive health disorders such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) significantly affect the quality of life for millions globally. With rising prevalence, earlier diagnoses, and more targeted treatments, the global therapeutics market for IBS and IBD is gaining rapid momentum.
